Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, 44000, Pakistan.
Shenzhen University Clinical Research Center for Neurological Diseases, Health Management Center, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University, Shenzhen, People's Republic of China.
Drug Des Devel Ther. 2021 Apr 1;15:1459-1476. doi: 10.2147/DDDT.S297013. eCollection 2021.
The development of resistance to available anticancer drugs is increasingly becoming a major challenge and new chemical entities could be unveiled to compensate this therapeutic failure. The current study demonstrated the synthesis of 2-aminothiazole [() and ()] and 2-aminopyridine [() and ()] derivatives that can target multiple cellular networks implicated in cancer development.
Biological assays were performed to investigate the antioxidant and anticancer potential of synthesized compounds. Redox imbalance and oxidative stress are hallmarks of cancer, therefore, synthesized compounds were preliminarily screened for their antioxidant activity using DPPH assay, and further five derivatives , , , , and , with significant antioxidant potential, were selected for investigation of in vitro anticancer potential. The cytotoxic activities were evaluated against the parent (A2780) and cisplatin-resistant (A2780CISR) ovarian cancer cell lines. Further, Molecular docking studies of active compounds were performed to determine binding affinities.
Results revealed that , , and displayed promising inhibition in cisplatin-resistant cell lines in comparison to parent cells in terms of both resistance factor (RF) and IC values. Moreover, proved to be most active compound in both parent and resistant cell lines with IC values 15.57 µM and 11.52 µM respectively. Our docking studies demonstrated that compounds , , and exhibited significant binding affinity with multiple protein targets of the signaling cascade.
Anticancer activities of compounds , , and in cisplatin-resistant cell lines suggested that these ligands may contribute as lead compounds for the development of new anticancer drugs.
对现有抗癌药物产生耐药性的问题日益严重,需要不断发掘新的化学实体来弥补这种治疗失败。本研究旨在合成 2-氨基噻唑[()]和 2-氨基吡啶[()]衍生物,以靶向多个与癌症发展相关的细胞信号网络。
通过生物测定法评估合成化合物的抗氧化和抗癌潜力。氧化还原失衡和氧化应激是癌症的标志,因此,本研究通过 DPPH 测定法初步筛选了合成化合物的抗氧化活性,随后选择了具有显著抗氧化活性的五个衍生物[()]、()、()、()和(),进一步研究其体外抗癌潜力。通过对亲本(A2780)和顺铂耐药(A2780CISR)卵巢癌细胞系的细胞毒性评估来评价其活性。此外,还进行了活性化合物的分子对接研究,以确定结合亲和力。
结果表明,与亲本细胞相比,()、()和()在顺铂耐药细胞系中具有更好的抑制作用,表现在耐药系数(RF)和 IC 值方面。此外,()在亲本和耐药细胞系中均表现出最强的活性,其 IC 值分别为 15.57µM 和 11.52µM。我们的对接研究表明,化合物()、()和()与信号转导级联的多个蛋白靶标具有显著的结合亲和力。
这些化合物在顺铂耐药细胞系中的抗癌活性表明,这些配体可能作为开发新型抗癌药物的先导化合物。